245 related articles for article (PubMed ID: 27571262)
1. Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.
Bailey SD; Desai K; Kron KJ; Mazrooei P; Sinnott-Armstrong NA; Treloar AE; Dowar M; Thu KL; Cescon DW; Silvester J; Yang SY; Wu X; Pezo RC; Haibe-Kains B; Mak TW; Bedard PL; Pugh TJ; Sallari RC; Lupien M
Nat Genet; 2016 Oct; 48(10):1260-6. PubMed ID: 27571262
[TBL] [Abstract][Full Text] [Related]
2. R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers.
Boldes T; Merenbakh-Lamin K; Journo S; Shachar E; Lipson D; Yeheskel A; Pasmanik-Chor M; Rubinek T; Wolf I
BMC Cancer; 2020 Jun; 20(1):531. PubMed ID: 32513126
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
4. Association of the Estrogen Receptor 1 Polymorphisms rs2046210 and rs9383590 with the Risk, Age at Onset and Prognosis of Breast Cancer.
Miedl H; Oswald D; Haslinger I; Gstoettner M; Wenzl R; Proestling K; Schneeberger C; Yotova I; Schreiber M
Cells; 2023 Feb; 12(4):. PubMed ID: 36831182
[TBL] [Abstract][Full Text] [Related]
5. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
8. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer.
Blanchard Z; Vahrenkamp JM; Berrett KC; Arnesen S; Gertz J
Genome Res; 2019 Sep; 29(9):1429-1441. PubMed ID: 31362937
[TBL] [Abstract][Full Text] [Related]
10. Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.
Stine ZE; McGaughey DM; Bessling SL; Li S; McCallion AS
Hum Mol Genet; 2011 Oct; 20(19):3746-56. PubMed ID: 21737465
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide functional synergy between amplified and mutated genes in human breast cancer.
Nikolsky Y; Sviridov E; Yao J; Dosymbekov D; Ustyansky V; Kaznacheev V; Dezso Z; Mulvey L; Macconaill LE; Winckler W; Serebryiskaya T; Nikolskaya T; Polyak K
Cancer Res; 2008 Nov; 68(22):9532-40. PubMed ID: 19010930
[TBL] [Abstract][Full Text] [Related]
13. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
[TBL] [Abstract][Full Text] [Related]
14. Tissue-Specific Expression of Estrogen Receptor 1 Is Regulated by DNA Methylation in a T-DMR.
Maekawa R; Sato S; Okada M; Lee L; Tamura I; Jozaki K; Kajimura T; Asada H; Yamagata Y; Tamura H; Yamamoto S; Sugino N
Mol Endocrinol; 2016 Mar; 30(3):335-47. PubMed ID: 26683811
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor (ESR1) mutation in bone metastases from breast cancer.
Bartels S; Christgen M; Luft A; Persing S; Jödecke K; Lehmann U; Kreipe H
Mod Pathol; 2018 Jan; 31(1):56-61. PubMed ID: 28799536
[TBL] [Abstract][Full Text] [Related]
16. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
[TBL] [Abstract][Full Text] [Related]
17. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
19. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Basudan A; Priedigkeit N; Hartmaier RJ; Sokol ES; Bahreini A; Watters RJ; Boisen MM; Bhargava R; Weiss KR; Karsten MM; Denkert C; Blohmer JU; Leone JP; Hamilton RL; Brufsky AM; Elishaev E; Lucas PC; Lee AV; Oesterreich S
Mol Cancer Res; 2019 Feb; 17(2):457-468. PubMed ID: 30355675
[TBL] [Abstract][Full Text] [Related]
20. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
